In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
OKN-007
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Biotech company acquires OMRF brain cancer drug
Agreement will expand clinical trials of glioblastoma drug